Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats

Psychopharmacology

Volumn 231, Issue 3, 2014, Pages 469-479

  Thomsen, Morgane ^a   Fulton, Brian S ^a   Caine, S Barak ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

Addiction; Choice; Cocaine; Muscarinic; Rats; Self administration; Xanomeline

Indexed keywords

COCAINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M4 RECEPTOR; XANOMELINE; DOPAMINE UPTAKE INHIBITOR; MUSCARINIC AGENT; PYRIDINE DERIVATIVE; THIADIAZOLE DERIVATIVE;

ABSTINENCE; ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; CHRONIC DRUG ADMINISTRATION; COCAINE DEPENDENCE; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERANCE; FOOD INTAKE; FOOD PREFERENCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; TRAINING; TREATMENT DURATION; AGONISTS; ANIMAL; BEHAVIOR, ADDICTIVE; DECISION MAKING; DRUG EFFECTS; DRUG SELF ADMINISTRATION; INSTRUMENTAL CONDITIONING; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; BEHAVIOR, ADDICTIVE; CHOICE BEHAVIOR; COCAINE; CONDITIONING, OPERANT; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOOD PREFERENCES; MALE; MUSCARINIC AGONISTS; PYRIDINES; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M4; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; THIADIAZOLES; TIME FACTORS;

EID: 84892806241     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3256-9     Document Type: Article

References (63)

1. Ahmed SH (2010) Validation crisis in animal models of drug addiction: beyond non-disordered drug use toward drug addiction. Neurosci Biobehav Rev 35:172-184
2. 4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology 28:1168-1175
3. Andersen MB, Werge T, Fink-Jensen A (2007) The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys. J Pharmacol Exp Ther 321:1179-1182
4. 2 antagonists. Behav Pharmacol 1:355-363
5. Bernard V, Normand E, Bloch B (1992) Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J Neurosci 12:3591-3600
6. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54:465-473
7. 1 muscarinic agonist zanomeline (LY246708/NNC11-0232). J Pharmacol Exp Ther 269:282-289
8. Bymaster FP, Whitesitt CA, Shannon HE, DeLapp N, Ward JS, Calligaro DO, Shipley LA, Buelke-Sam JL, Bodick NC, Farde L, Sheardown MJ, Olesen PH, Hansen KT, Suzdak PD, Swedberg MDB, Sauerberg P, Mitch CH (1997) Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev Res 40:158-170
9. De La Garza R 2nd, Mahoney JJ 3rd, Culbertson C, Shoptaw S, Newton TF (2008a) The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. Pharmacol Biochem Behav 89:200-208
10. De La Garza R, Shoptaw S, Newton TF (2008b) Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers. Int J Neuropsychopharmacol 11:729-741
11. De La Garza R 2nd, Newton TF, Haile CN, Yoon JH, Nerumalla CS, Mahoney JJ 3rd, Aziziyeh A (2011) Rivastigmine reduces Likely to use methamphetamine in methamphetamine-dependent volunteers. Prog Neuropsychopharmacol Biol Psychiatry 37:141-146
12. 1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex. J Pharmacol Exp Ther 323:868-876
13. 4 preferring muscarinic receptor agonist xanomeline. J Neurosci 31:5905-5908
14. Di Chiara G, Morelli M, Consolo S (1994) Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci 17:228-233
15. Friedman JI (2004) Cholinergic targets for cognitive enhancement in schizophrenia: Focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacol (Berl) 174:45-53
16. Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D, Moeller FG (2001) Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 21:522-526
17. Grasing K, He S, Yang Y (2008) Dose-related effects of the acetylcholinesterase inhibitor tacrine on cocaine and food self-administration in rats. Psychopharmacol (Berl) 196:133-142
18. Grasing K, He S, Yang Y (2009) Long-lasting decreases in cocaine-reinforced behavior following treatment with the cholinesterase inhibitor tacrine in rats selectively bred for drug self-administration. Pharmacol Biochem Behav 94:169-178
19. Grasing K, Mathur D, Newton TF, DeSouza C (2010) Donepezil treatment and the subjective effects of intravenous cocaine in dependent individuals. Drug Alcohol Depend 107:69-75
20. Greenwald MK, Lundahl LH, Steinmiller CL (2010) Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers. Neuropsychopharmacology 35:2624-2637
21. Haney M, Spealman R (2008) Controversies in translational research: drug self-administration. Psychopharmacol (Berl) 199:403-419
22. Haney M, Ward AS, Foltin RW, Fischman MW (2001) Effects of ecopipam, a selective dopamine d1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacol (Berl) 155:330-337
23. Haney M, Rubin E, Foltin RW (2010) Aripiprazole maintenance increases smoked cocaine self-administration in humans. Psychopharmacol (Berl) 216:379-387
24. Heinrich JN, Butera JA, Carrick T, Kramer A, Kowal D, Lock T, Marquis KL, Pausch MH, Popiolek M, Sun SC, Tseng E, Uveges AJ, Mayer SC (2009) Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol 605:53-56
25. Hersch SM, Gutekunst CA, Rees HD, Heilman CJ, Levey AI (1994) Distribution of M1-M4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J Neurosci 14:3351-3363
26. Hikida T, Kaneko S, Isobe T, Kitabatake Y, Watanabe D, Pastan I, Nakanishi S (2001) Increased sensitivity to cocaine by cholinergic cell ablation in nucleus accumbens. Proc Natl Acad Sci U S A 98:13351-13354
27. Hikida T, Kitabatake Y, Pastan I, Nakanishi S (2003) Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine. Proc Natl Acad Sci U S A 100:6169-6173
28. Kane BE, Grant MK, El-Fakahany EE, Ferguson DM (2008) Synthesis and evaluation of xanomeline analogs - probing the wash-resistant phenomenon at the M1 muscarinic acetylcholine receptor. Bioorg Med Chem 16:1376-1392
29. Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S, Blecha L, Lowenstein W, Martinot JL, Reynaud M, Lepine JP (2008) New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 11:425-438
30. 1 muscarinic receptor agonist, 77-LH-28-1. Br J Pharmacol 154:1104-1115
31. 4 muscarinic receptors in rat brain. J Pharmacol Exp Ther 322:316-323
32. Mark GP, Kinney AE, Grubb MC, Zhu X, Finn DA, Mader SL, Berger SP, Bechtholt AJ (2006) Injection of oxotremorine in nucleus accumbens shell reduces cocaine but not food self-administration in rats. Brain Res 1123:51-59
33. Mirza NR, Peters D, Sparks RG (2003) Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Reviews 9:159-186
34. Negus SS (2003) Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with d-amphetamine and flupenthixol. Neuropsychopharmacology 28:919-931
35. Negus SS, Banks ML (2011) Making the right choice: lessons from drug discrimination for research on drug reinforcement and drug self-administration. In: Glennon RA, Young R (eds) Drug discrimination: applications to medicinal chemistry and drug studies. John Wiley and Sons, Hoboken, pp 361-388
36. Negus SS, Mello NK (2003) Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacol (Berl) 167:324-332
37. Newman JL, Negus SS, Lozama A, Prisinzano TE, Mello NK (2010) Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys. Exp Clin Psychopharmacol 18:395-408
38. 1-like receptor signalling in rat nucleus accumbens. Eur J Pharmacol 448:105-111
39. Rush CR, Stoops WW, Hays LR (2009) Cocaine effects during d-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy. Drug Alcohol Depend 99:261-271
40. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S (2008) Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 64:145-152
41. Shannon HE, Bymaster FP, Calligaro DO, Greenwood B, Mitch CH, Sawyer BD, Ward JS, Wong DT, Olesen PH, Sheardown MJ et al (1994) Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther 269:271-281
42. Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, Jeppesen L, Sheardown MJ, Sauerberg P, Fink-Jensen A (2000) Xanomeline, an m(1)/m(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res 42:249-259
43. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165:1033-1039
44. Shoaib M, Swanner LS, Beyer CE, Goldberg SR, Schindler CW (1998) The GABAB agonist baclofen modifies cocaine self-administration in rats. Behav Pharmacol 9:195-206
45. Smiley JF, Levey AI, Mesulam MM (1999) m2 muscarinic receptor immunolocalization in cholinergic cells of the monkey basal forebrain and striatum. Neuroscience 90:803-814
46. Smith JE, Co C, Yin X, Sizemore GM, Liguori A, Johnson WE 3rd, Martin TJ (2004) Involvement of cholinergic neuronal systems in intravenous cocaine self-administration. Neurosci Biobehav Rev 27:841-850
47. Sofuoglu M (2010) Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction 105:38-48
48. Sofuoglu M, Mooney M (2009) Cholinergic functioning in stimulant addiction: implications for medications development. CNS Drugs 23:939-952
49. Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, Kennett GA, Lightowler S, Sheardown MJ, Syed R, Upton RL, Wadsworth G, Weiss SM, Wyatt A (2001) The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 299:782-792
50. Takamatsu Y, Yamanishi Y, Hagino Y, Yamamoto H, Ikeda K (2006) Differential effects of donepezil on methamphetamine and cocaine dependencies. Ann N Y Acad Sci 1074:418-426
51. The National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals (2011). Guide for the care and use of laboratory animals, 8th edn. National Academies Press (US), Washington (DC)
52. Thomsen M, Caine SB (2005) Chronic intravenous drug self-administration in rats and mice. Curr Protoc Neurosci Chapter 9: Unit 9 20
53. Thomsen M, Fink-Jensen A, Woldbye PD, Wortwein G, Sager TN, Holm R, Pepe LM, Caine SB (2008) Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats. Psychopharmacol (Berl) 201:43-53
54. Thomsen M, Conn PJ, Lindsley C, Wess J, Boon JY, Fulton BS, Fink-Jensen A, Caine SB (2010a) Attenuation of cocaine's reinforcing and discriminative stimulus effects via muscarinic M1 acetylcholine receptor stimulation. J Pharmacol Exp Ther 332:959-969
55. 4 muscarinic receptors in mice. Psychopharmacology 208:401-416
56. 4 receptors to muscarinic agonist-mediated attenuation of the cocaine discriminative stimulus in mice. Psychopharmacol (Berl) 220:673-685
57. Thomsen M, Barrett AC, Negus SS, Caine SB (2013) Cocaine versus food choice procedure in rats: environmental manipulations and effects of amphetamine. J Exp Anal Behav 99:211-233
58. Watson J, Brough S, Coldwell MC, Gager T, Ho M, Hunter AJ, Jerman J, Middlemiss DN, Riley GJ, Brown AM (1998) Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol 125:1413-1420
59. Weiner DM, Levey AI, Brann MR (1990) Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci U S A 87:7050-7054
60. Wess J, Eglen RM, Gautam D (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6:721-733
61. Williams MJ, Adinoff B (2008) The role of acetylcholine in cocaine addiction. Neuropsychopharmacology 33:1779-1797
62. Winhusen TM, Somoza EC, Harrer JM, Mezinskis JP, Montgomery MA, Goldsmith RJ, Coleman FS, Bloch DA, Leiderman DB, Singal BM, Berger P, Elkashef A (2005) A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 100(Suppl 1):68-77
63. Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA (2009) Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. Eur J Pharmacol 603:147-149